Leukemia Clinical Trials in Cleveland

Showing 741-760 of 802 trials

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00068315

This phase I trial is studying the side effects and best dose of bortezomib when given together with fludarabine with or without rituximab in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with fludarabine with or without rituximab may kill more cancer cells.

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHematopoietic/Lymphoid CancerNodal Marginal Zone B-cell Lymphoma+9 more

National Cancer Institute (NCI)18 participantsStarted Jul 2003

Canton, Ohio, United States • Cleveland, Ohio, United States • Cleveland, Ohio, United States +4 more locations

COMPLETEDPHASE3< 1 mile

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

NCT00002812

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.

Leukemia

Children's Oncology Group2,078 participantsStarted Sep 1996

Long Beach, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +32 more locations

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

Leukemia Trials in Other Cities

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Other Conditions in Cleveland